Key Highlights
- Neogen Corporation's share was trading at $5.92 as of December 1st.
- NEOG’s trailing and forward P/E were 822.50 and 16.00 respectively according to Yahoo Finance.
- Soleno Therapeutics (SLNO) Jumps 13.46% as Competitor Fails Prader-Willi Treatment Trial Romaset/Shutterstock. com Neogen presents a compelling opportunity to invest in a high-quality food and animal safety platform that has undergone significant operational strain but is now approaching an inflection point.
- Following its 2022 merger with 3M’s Food Safety division—a deal that doubled the share count, added $1 billion of debt, and required heavy capital investments—the company struggled with duplicative manufacturing costs, delays in transitioning 3M’s high-margin Petrifilm production, and a sprawling portfolio lacking strategic focus.
- These issues drove the stock down more than 80% from pre-deal levels, pushing valuation to ~10x FY27 EBITDA—near financial-crisis lows despite Neogen owning some of the industry’s most valuable testing, sanitation, and sampling assets.
